Zambon exercises option on Merck reject safinamide as Newron shakes off the old
This article was originally published in Scrip
Executive Summary
Zambon has firmed up its collaboration with fellow Italian firm Newron, exercising the option it took out on the late-stage Parkinson's disease treatment safinamide in April (scripintelligence.com, 5 April 2012). Concurrent with the news, Newron reported positive top-line results from the last two Phase III studies of safinamide and said that its long-serving CEO Luca Benatti would be leaving the company to pursue another opportunity. CFO Stefan Weber is to replace him at the top.